Rezdiffra: An FDA Approved Treatment for NASH

Note: NASH is now known as MASH (Metabolic dysfunction-associated steatohepatitis)

Earlier this year, big news in the treatment of MASH was announced and The Liver Institute at Methodist Dallas and the Clinical Research Institute at Methodist Dallas Medical Center played a role.

The FDA approved Rezdiffra, the first and only medication for the treatment of MASH.

We were chosen as a study center during different stages of the clinical trial for this game-changing liver disease medication.

In conjunction with diet and exercise, Rezdiffra (resmetirom) is available to adults with noncirrhotic MASH who have moderate to advanced liver fibrosis.

In a press release by Rezdiffra developer, Madrigal Pharmaceuticals, it stated that the accelerated approval from the FDA was based on “Phase 3 data demonstrating that Rezdiffra improved liver fibrosis and resolved MASH in patients with moderate to advanced liver fibrosis.”

How does Rezdiffra help?

This once-daily oral tablet works by targeting key underlying causes of MASH. Known as a THR-ꞵ agonist (a thyroid hormone receptor-beta), it binds to and activates the THR-ꞵ receptors in the liver, kidney, thyroid and other organs. This process promotes the breakdown of liver fat.

Clinical studies showed that after one year of treatment, patients taking Rezdiffra showed significant improvement on two important outcomes - fibrosis improvement and MASH resolution.

What does this mean for patients with MASH?

It means they have another option to consider in the treatment of their liver disease. Managing liver disease is a complex process that involves many factors and until recently, there was no medication available to help manage MASH.

As part of the clinical trials team for Rezdiffra, our liver specialists saw the evidence that this liver directed therapy can help improve fibrosis and resolve MASH before a patient progresses to cirrhosis. If you feel this treatment option could be right for you, make an appointment today to learn more.

To learn more about Rezdiffra: https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-fda-approval-rezdiffratm